Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Exercise-induced muscle damage research spans two mechanistic clusters: structural tissue repair and post-exercise inflammation resolution (BPC-157, TB-500), and metabolic/GH-axis recovery driving mitochondrial adaptation and overnight protein synthesis (MOTS-c, Ipamorelin). Three of the four peptides are on the July 23–24, 2026 FDA PCAC advisory docket. This guide covers mechanisms, evidence quality, and COA verification — not dosing or medical advice.
FDA PCAC Advisory Meeting — July 23–24, 2026
BPC-157, TB-500, MOTS-c — three peptides in this guide — are on the FDA Pharmacy Compounding Advisory Committee (PCAC) July 23–24, 2026 advisory docket. BPC-157 and TB-500 were also removed from Category 2 in April 2026, but this does not authorize compounding. Full regulatory status →
BPC-157 and TB-500 both address the structural dimension of exercise-induced muscle damage: BPC-157 drives angiogenesis (VEGF/eNOS) to resolve post-exercise microvasculature ischemia and activates FAK-paxillin cytoskeletal repair signaling; TB-500 manages the cytoskeletal remodeling (G-actin sequestration, Z-disc rebuilding) and suppresses the NLRP3 inflammasome activation that produces DOMS-driving IL-1β. Both are on the PCAC docket and were removed from Category 2 in April 2026.
Pentadecapeptide (gastric juice-derived, 15 aa)
G-actin sequestering peptide (43 aa, Thymosin Beta-4)
MOTS-c and Ipamorelin address the metabolic and anabolic dimensions of post-exercise recovery. MOTS-c activates AMPK via the folate–AICAR pathway to drive mitochondrial biogenesis — amplifying the supercompensation signal that makes training adaptation possible. Ipamorelin generates selective pulsatile GH release (no cortisol spike) to maximize overnight IGF-1-driven protein synthesis in damaged myofibers. MOTS-c is on the PCAC docket; Ipamorelin was removed from Category 2 in April 2026 but is not on the PCAC docket.
Mitochondria-derived peptide (16 aa, mtDNA-encoded)
Selective GH secretagogue pentapeptide (5 aa)
| Peptide | Cat-2 Removed (Apr 2026) | PCAC Docket (July 23–24, 2026) |
|---|---|---|
| BPC-157 | Yes — removed from Cat-2 | On docket |
| TB-500 | Yes — removed from Cat-2 | On docket |
| MOTS-c | Not in Apr 2026 removals | On docket |
| Ipamorelin | Yes — removed from Cat-2 | Not on docket |
Category 2 removal does not authorize compounding or place peptides on the 503A approved list. The PCAC is advisory; the FDA issues final rules after the meeting. Full regulatory timeline →
The four athletic-recovery peptides span an ~4.8× molecular weight range — from Ipamorelin (~1,043 Da) to TB-500 (~4,964 Da) — and verification requirements scale accordingly.
HPLC purity ≥98% plus intact-mass ESI-MS at ~1,043 Da [M+H]⁺. Key substitution risk: GHRP-2 (~817 Da) or GHRP-6 (~873 Da). Mass confirm eliminates analog fraud.
RP-HPLC purity ≥98% plus intact-mass MS at ~1,419 Da. One of the most-tested research peptides with third-party lot data in the Disclosed Labs database. Third-party lab + lot number are baseline.
Intact-mass MS essential — confirm [M+2H]²⁺ at ~1,087 Da or [M+H]⁺ at ~2,173 Da. Shorter commercial history than BPC-157/TB-500; third-party COA from established labs (Janoshik, Vanguard, MDx) is more important as a quality signal.
Intact-mass MS non-negotiable. HPLC-MS coupling preferred over standalone HPLC. At 43 residues: truncation artifacts, Met(8) oxidation, Asn/Gln deamidation all pass HPLC but fail MS. LC-MS/MS sequence fragment confirmation is gold standard.
Verified COA data for BPC-157, TB-500, and Ipamorelin from multiple vendors is available in the Disclosed Labs peptide database. MOTS-c lot coverage is growing as independent lab testing expands.
Exercise-induced muscle damage (EIMD) research has focused on four mechanistically distinct peptides that address different phases of the recovery process: vascular repair, myofibril structural rebuilding, mitochondrial adaptation, and overnight GH-axis protein synthesis. BPC-157, a synthetic pentadecapeptide from gastric juice (~1,419 Da), is studied for its VEGF/eNOS-driven angiogenesis that resolves post-exercise ischemia in damaged microvasculature — the same mechanism relevant to tendon, GI, and musculoskeletal healing. TB-500 (Thymosin Beta-4, ~4,964 Da, 43 aa) is an endogenous G-actin sequestering peptide whose LKKTETQ active fragment participates in cytoskeletal remodeling critical to damaged myofibril repair and also suppresses post-exercise NLRP3 inflammasome activation (the driver of delayed-onset muscle soreness). MOTS-c (~2,173 Da, 16 aa) is a mitochondria-derived peptide encoded in the 12S rRNA mitochondrial gene that activates AMPK and the folate–AICAR pathway; Lee et al. (2015, Cell Metabolism) demonstrated that MOTS-c levels rise during exercise in mice, exogenous administration improves endurance and reduces fat accumulation, and the mechanism operates through mitochondrial biogenesis and insulin-glucose regulation — positioning it as a recovery-phase mitochondrial adaptation signal. Ipamorelin (~1,043 Da, 5 aa) is a selective growth hormone secretagogue (GHS-R agonist) that stimulates pulsatile GH release without the cortisol or prolactin elevation seen with GHRP-2/GHRP-6; the GH pulse it induces increases overnight insulin-like growth factor-1 (IGF-1) production, which drives protein synthesis in damaged muscle fiber during sleep. All four are sold as research chemicals; none are FDA-approved for any athletic or recovery indication.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide (15 amino acids, ~1,419 Da) originally isolated from human gastric juice by the Sikiric group at the University of Zagreb. Its primary relevance to exercise-induced recovery is its pro-angiogenic and vascular-repair mechanism: BPC-157 upregulates vascular endothelial growth factor (VEGF) and activates endothelial nitric oxide synthase (eNOS), driving new capillary formation and vasodilation in microvasculature damaged by high-intensity exercise. This is relevant because exercise-induced muscle damage produces local ischemia — inadequate blood flow to damaged sarcomeres — that extends the inflammatory phase and delays collagen and myofibril remodeling. By resolving ischemia, BPC-157 shortens this inflammatory window. At the cytoskeletal level, BPC-157 modulates the FAK-paxillin signaling axis: focal adhesion kinase (FAK) and paxillin are mechanosensing scaffold proteins that regulate cell migration, extracellular matrix (ECM) remodeling, and myosatellite cell proliferation following muscle damage — all critical steps in myofibril repair. Novaes et al. (2019, European Journal of Pharmacology) showed BPC-157 accelerated functional tendon recovery in a rodent model via FAK activation and collagen fiber re-alignment. The anti-inflammatory component: BPC-157 suppresses NF-κB transcriptional activation and reduces downstream COX-2 and TNF-α production, blunting the EIMD-driven inflammatory cascade without fully abolishing the pro-regenerative inflammatory signal. This distinguishes it from NSAIDs mechanistically — BPC-157 does not directly inhibit COX-2 enzyme activity; it reduces COX-2 transcription, which may preserve some prostaglandin-mediated satellite cell activation needed for adaptation. The evidence base is broad preclinical — GI, tendon, musculoskeletal, neurological models from the Sikiric group — but no human RCTs exist for exercise recovery endpoints. BPC-157 was among the 12 peptides removed from FDA Category 2 in April 2026 and is on the July 23–24 PCAC advisory docket.
TB-500 (Thymosin Beta-4) is a 43-amino-acid G-actin sequestering peptide (~4,964 Da) ubiquitous in eukaryotic cells and particularly abundant in platelets and macrophages. Its role in exercise-induced muscle damage recovery operates through three converging mechanisms. First, and most structurally important, is G-actin sequestration. TB-500 binds globular (G-actin) monomers in a 1:1 stoichiometric complex via its LKKTETQ heptapeptide sequence, preventing their polymerization into F-actin (filamentous actin). After intense eccentric exercise, Z-disc disruption and sarcomere damage create an excess of G-actin released from disrupted thin filaments; TB-500's sequestration of this pool controls the initial cytoskeletal chaos and facilitates orderly remodeling through cofilin and profilin-mediated F-actin turnover. Malinda et al. (1997, FASEB Journal) demonstrated that Thymosin Beta-4 promoted cell migration — a prerequisite for myosatellite cell recruitment to damaged fibers — via this actin-dynamics pathway. Second, post-exercise NLRP3 inflammasome suppression: high-intensity exercise produces mitochondrial ROS that prime and activate the NLRP3 inflammasome in muscle-resident macrophages, generating IL-1β and IL-18 — the primary mediators of delayed-onset muscle soreness (DOMS) and prolonged recovery. Smart et al. (2010, Journal of Investigative Dermatology) showed Thymosin Beta-4 suppresses NF-κB nuclear translocation and downstream NLRP3 priming; Crockford (2007, Annals of the New York Academy of Sciences) documented systemic anti-inflammatory effects in cardiac and musculoskeletal models. Third, Wnt/β-catenin pathway activation: TB-500 promotes Wnt signaling, which both suppresses NLRP3 priming (through AXIN competition with β-catenin destruction complex) and activates myosatellite cell self-renewal — directly supporting the myogenic regeneration phase. TB-500 was removed from FDA Category 2 in April 2026 and is on the July 23–24 PCAC docket. At ~4,964 Da, it requires more stringent COA verification than small peptides.
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondria-derived peptide (~2,173 Da) encoded not in the nuclear genome but in the mitochondrial 12S ribosomal RNA gene — a discovery reported by Lee et al. (2015, Cell Metabolism) that established a new class of mitochondria-encoded signaling peptides called mitochondria-derived peptides (MDPs). Its exercise physiology relevance is direct: Lee et al. showed that MOTS-c levels in mouse serum increase during exercise and that exogenous MOTS-c administration improved endurance exercise performance, reduced body fat, and enhanced insulin sensitivity in aged mice on a high-fat diet. The core molecular mechanism is AMPK activation via the folate–AICAR pathway: MOTS-c enters the cytoplasm and inhibits the folate cycle enzyme AICAR transformylase (ATIC), causing an accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) — a known AMPK activator. AMPK activation in skeletal muscle during recovery drives: (1) mitochondrial biogenesis via PGC-1α nuclear translocation, increasing the mitochondrial density that underlies improved oxidative capacity in subsequent training sessions; (2) glucose uptake through GLUT4 translocation, independently of insulin; (3) fatty acid oxidation via ACC (acetyl-CoA carboxylase) phosphorylation and CPT-1 activation. The recovery-phase angle is distinct from the during-exercise role: post-exercise AMPK-PGC-1α signaling is what drives the mitochondrial supercompensation (the physiological basis of training adaptation). MOTS-c is proposed to amplify this signal. A 2021 human study by Bhullar et al. examined MOTS-c in insulin resistance contexts. The athletic recovery data remain primarily from the Lee 2015 rodent model; the translation to human exercise recovery is mechanistically plausible but not yet established in RCTs. MOTS-c is on the FDA PCAC July 23–24, 2026 advisory docket. It was not among the April 2026 Category 2 removals.
Ipamorelin is a synthetic pentapeptide (~1,043 Da, 5 amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that selectively agonizes the growth hormone secretagogue receptor (GHS-R1a) in the pituitary somatotrophs. Its selectivity is its defining pharmacological feature: among the GH secretagogues, Ipamorelin produces robust GH pulses with minimal or no stimulation of cortisol, prolactin, or ACTH — a pattern documented by Raun et al. (1998, European Journal of Endocrinology) who first characterized Ipamorelin's clean GH-releasing profile compared to GHRP-2 and GHRP-6. This selectivity matters for recovery because elevated cortisol — the stress glucocorticoid — is catabolic: it promotes protein catabolism, suppresses satellite cell proliferation, and blunts IGF-1 signaling. GHRP-2 and GHRP-6 produce meaningful cortisol increases alongside GH; Ipamorelin does not, preserving the anabolic GH→IGF-1 axis without the catabolic cortisol interference. The recovery mechanism: GH pulses (particularly overnight during deep sleep) stimulate hepatic and local IGF-1 production; IGF-1 binds the IGF-1 receptor (IGF-1R) on satellite cells and myocytes, activating the PI3K→Akt→mTOR signaling cascade that drives protein synthesis (net positive nitrogen balance), satellite cell proliferation, and myofibril hypertrophic repair. This mechanism is especially relevant in the post-exercise protein synthesis window (hours 12–72 post-training). Ipamorelin was among the 12 peptides removed from FDA Category 2 (the 503B significant-safety-concern list) in April 2026 — a regulatory procedural step that does not authorize compounding or place it on the approved list. It is NOT on the FDA PCAC July 23–24 advisory docket. No human RCTs for athletic recovery or muscle repair exist; the mechanism is inferred from GH physiology and GHRP pharmacology literature.
The distinction maps onto three different physiological processes that share some peptides but address fundamentally different endpoints. Healing research targets acute tissue injury — ligament tears, tendon ruptures, surgical wounds, fracture repair. The endpoint is structural tissue restoration: collagen fiber alignment, granulation tissue formation, angiogenesis at the wound margin. Peptides studied in this context (BPC-157, TB-500, GHK-Cu, KPV) focus on wound closure, macrophage polarization toward M2 (pro-resolution), and ECM remodeling. Athletic recovery, by contrast, targets exercise-induced muscle damage (EIMD) — a physiologically normal process of microtearing in myofibrils (especially during eccentric loading) that triggers the adaptive supercompensation cycle. The endpoint is not wound closure but return-to-training time, reduced DOMS, and preservation of the mitochondrial adaptation signal. The recovery process involves Z-disc repair, satellite cell activation, NLRP3-mediated inflammation resolution, and mitochondrial biogenesis — making MOTS-c's AMPK mechanism uniquely relevant here, with no analog in acute injury healing. Muscle-growth research targets hypertrophy — the net anabolic increase in myofibril cross-sectional area following progressive overload. This is a weeks-to-months process driven by GH-axis peptides (CJC-1295, GHRP-2, Ipamorelin, IGF-1 LR3) and their sustained IGF-1→mTOR activation; the relevant peptides (Sermorelin, Tesamorelin, MK-677) maximize GH/IGF-1 exposure over time rather than targeting the acute recovery window. Athletic recovery occupies the middle ground: it uses BPC-157 and TB-500 (shared with healing for structural repair), MOTS-c (unique to metabolic/mitochondrial recovery, absent from the healing context), and Ipamorelin (from the GH-axis, but in an acute pulse context rather than the sustained hypertrophy application). In practice, BPC-157 appears across many guides on this platform because its VEGF/NF-κB mechanism is genuinely relevant across tissue types; this guide focuses specifically on the EIMD and post-training recovery angle rather than acute injury or mass accretion.
Three of the four peptides in this guide are on the FDA Pharmacy Compounding Advisory Committee (PCAC) docket for the July 23–24, 2026 advisory meeting: BPC-157, TB-500, and MOTS-c. The PCAC reviews nominations to the 503A Bulk Drug Substances List (the list of compounds that licensed compounding pharmacies may compound without an FDA-approved finished drug application) and makes advisory recommendations — the FDA issues any final rule typically 6–18 months after the meeting. BPC-157 and TB-500 were also among the 12 peptides the FDA removed from Category 2 (the 503B significant-safety-concern list) in April 2026; this removal does not authorize compounding for any indication — it removes the 'significant safety risk' designation under the 503B framework. MOTS-c was not part of the April 2026 Category 2 removals; it enters the PCAC process through the nominations docket for 503A review. Ipamorelin was included in the April 2026 Category 2 removals but is NOT on the July 2026 PCAC advisory docket. Until the FDA issues final rules, all four remain available as research chemicals for laboratory and scientific research use. In April 2026 the FDA removed 12 peptides from Category 2; this does not place them on the Category 1 (503A) list or authorize compounding. The PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations — the FDA issues any final rule later. Consult a licensed healthcare provider and regulatory attorney for current guidance on any compounding or research procurement.
The four peptides span a ~4.8× molecular weight range — from Ipamorelin (~1,043 Da) to TB-500 (~4,964 Da) — and COA rigor scales with complexity. Ipamorelin (~1,043 Da, pentapeptide): HPLC purity ≥98% is table stakes; intact-mass ESI-MS confirming [M+H]⁺ at ~1,043 Da distinguishes Ipamorelin from structural analogs. Common substitution risk: GHRP-2 (~817 Da) or GHRP-6 (~873 Da) at lower cost. Mass spec exact-mass confirmation eliminates substitution. BPC-157 (~1,419 Da, 15 aa): one of the most widely tested research peptides; third-party lot verification is available in the Disclosed Labs COA database for multiple vendors (Janoshik, Vanguard, ILS, MDx). RP-HPLC purity ≥98% plus intact-mass MS of ~1,419 Da [M+H]⁺ or [M+2H]²⁺. Well-characterized synthesis; truncation is the main quality failure mode. MOTS-c (~2,173 Da, 16 aa): at 16 residues, HPLC purity alone cannot confirm sequence — intact-mass MS is necessary. Confirm [M+2H]²⁺ at ~1,087 Da or [M+H]⁺ at ~2,173 Da. MOTS-c has a shorter commercial history than BPC-157 or TB-500; independent lab testing records are sparser, making third-party COA from established labs (Janoshik, Vanguard, MDx) more important as a quality signal. TB-500 (~4,964 Da, 43 aa): the most analytically demanding peptide in this guide. Intact-mass MS is non-negotiable; HPLC-MS coupling is preferred over standalone HPLC. At 43 residues, truncation artifacts (incomplete synthesis terminating before C-terminus), Met oxidation at position 8, and Asn/Gln deamidation are common and undetectable by HPLC alone. LC-MS/MS sequence fragment coverage confirmation is the gold standard. Verify that the lot number appears in a recognized third-party lab database before use in any research context.
Research context only. All content on this page is for scientific research reference. These peptides are sold as research chemicals, not for human administration. Nothing here constitutes medical advice, dosing guidance, or a recommendation to use any substance. Consult a licensed healthcare provider before making any health decisions.
Disclosed Labs